Humana (HUM) Valuation Check After Prolonged Share Price Weakness

Simply Wall St.

Jan 28

If you are wondering whether Humana's current share price reflects its true worth, you are not alone, especially after a tough run for the stock. The share price closed at US$207.93, with returns of a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606976047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606976047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606976047?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955","is_english":true,"pubTime":"2026-01-28 11:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606976047","market":"us","top_or_hot":-1,"title":"Humana (HUM) Valuation Check After Prolonged Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Humana's current share price reflects its true worth, you are not alone, especially after a tough run for the stock. The share price closed at US$207.93, with returns of a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-valuation-check-after-prolonged-share-price-weakn\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humana (HUM) Valuation Check After Prolonged Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumana (HUM) Valuation Check After Prolonged Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-28 11:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-valuation-check-after-prolonged-share-price-weakn><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Humana's current share price reflects its true worth, you are not alone, especially after a tough run for the stock. The share price closed at US$207.93, with returns of a...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-valuation-check-after-prolonged-share-price-weakn\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-valuation-check-after-prolonged-share-price-weakn","article_id":"2606976047","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/29618-main-header/1756204961955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hum/humana/news/humana-hum-valuation-check-after-prolonged-share-price-weakn","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2606976047","pubTimestamp":1769571590,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Humana's current share price reflects its true worth, you are not alone, especially after a tough run for the stock.\nThe share price closed at US$207.93, with returns of a 22.4% decline over 7 days, 19.7% decline over 30 days, 21.4% decline year to date, 30.4% decline over 1 year, 58.0% decline over 3 years and 42.3% decline over 5 years.\nRecent coverage of Humana has focused on the pressures facing managed care companies and shifting expectations around health...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4154":"管理型保健护理","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","HUM":"哈门那","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4585":"ETF&股票定投概念","BK7500":"支付概念","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4566":"资本集团","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","HUM.AU":"HUMM GROUP LTD","BK7093":"消费信贷"},"translate_title":"股价长期疲软后Humana(HUM)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUM.AU":1.5,"DCF":1,"HUM":1},"content_text":"If you are wondering whether Humana's current share price reflects its true worth, you are not alone, especially after a tough run for the stock. The share price closed at US$207.93, with returns of a 22.4% decline over 7 days, 19.7% decline over 30 days, 21.4% decline year to date, 30.4% decline over 1 year, 58.0% decline over 3 years and 42.3% decline over 5 years. Recent coverage of Humana has focused on the pressures facing managed care companies and shifting expectations around health plan costs and utilization. These themes have added context to the share price weakness, as investors reassess how much risk they are taking on in this part of the healthcare sector. Against that backdrop, Humana currently scores 5/6 on our valuation checks. This sets up a closer look at how methods like discounted cash flow and multiples stack up, and hints at an even richer way to think about valuation that we will come back to at the end of this article.  Find out why Humana's -30.4% return over the last year is lagging behind its peers. AdvertisementApproach 1: Humana Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to the present. For Humana, the model uses last twelve months free cash flow of about $1.24b and then applies a 2 Stage Free Cash Flow to Equity approach. Analysts provide explicit estimates out to 2030, with projected free cash flow of $4.92b at that point. Beyond those analyst inputs, Simply Wall St extrapolates additional years to complete the 10 year path, with annual projections between roughly $2.54b and $6.19b over 2026 to 2035, each discounted back to today. When you add up those discounted cash flows, the model arrives at an estimated intrinsic value of about $999.29 per share. Compared with the recent share price of $207.93, this implies a 79.2% discount, which indicates that the stock screens as materially undervalued on this DCF view. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Humana is undervalued by 79.2%. Track this in your watchlist or portfolio, or discover 881 more undervalued stocks based on cash flows. HUM Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Humana. Approach 2: Humana Price vs Earnings For a profitable company like Humana, the P/E ratio is a straightforward way to connect what you pay per share with the earnings the business is already generating. It helps you see how much the market is currently paying for each dollar of earnings. What counts as a \"normal\" P/E depends on how fast investors expect earnings to grow and how much risk they see in those earnings. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk usually lines up with a lower P/E. Humana currently trades on a P/E of 19.37x. That sits slightly above the peer average of 18.81x and below the broader Healthcare industry average of 23.43x. Simply Wall St also calculates a Fair Ratio of 36.82x for Humana. This Fair Ratio is a proprietary estimate of the P/E that might be appropriate given factors such as earnings growth, industry, profit margins, market cap and risk profile. Because the Fair Ratio rolls those company specific factors together, it can be more tailored than a simple comparison with peers or the industry. With Humana’s current P/E of 19.37x sitting below the Fair Ratio of 36.82x, the shares appear undervalued on this metric. Result: UNDERVALUED NYSE:HUM P/E Ratio as at Jan 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1426 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Humana Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is simply your own story about Humana that sits behind the numbers, where you spell out what you think is a reasonable fair value and what you expect for future revenue, earnings and margins. On Simply Wall St, Narratives live in the Community page and connect that story to a full forecast, then to a fair value that you can compare directly with today’s share price to help you judge whether Humana looks expensive, cheap or somewhere in between for you. Because Narratives on the platform are refreshed when new information such as news or earnings is added, your view can stay current without you having to rebuild everything from scratch. You can also see how other investors’ Narratives on Humana span a wide range of fair values when they plug in different assumptions, even though they are all looking at the same company. Do you think there's more to the story for Humana? Head over to our Community to see what others are saying! NYSE:HUM 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Humana might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}